Abstract: Disclosed are various embodiments of temperature-compensated relaxation oscillator circuits that may be fabricated using conventional CMOS manufacturing techniques. The relaxation oscillator circuits described herein exhibit superior low temperature coefficient performance characteristics, and do not require the use of expensive off-chip high precision resistors to effect temperature compensation. Positive and negative temperature coefficient resistors arranged in a resistor array offset one another to provide temperature compensation in the relaxation oscillator circuit.

Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PSMA with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancer.

Abstract: The present invention provides anti-ED-B antibodies, antibody fragments, and antibody mimetics and such antibodies conjugated to a partner molecule, wherein the antibody or the antibody-partner molecule conjugate provides a therapeutic effect regardless of whether the ED-B-antibody or ED-B-conjugate complex is internalized within a targeted cell.

Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19 antibodies, expression vectors, host cells and methods for expressing the CD19 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the CD19 antibodies are also provided. Methods for detecting CD19, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma, are disclosed.

Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing the prodrug are also disclosed.

Abstract: This invention relates to a diffuser for an aeration system, comprising a base, a diaphragm and a valve member attached to the diaphragm. The base is provided with a valve seat for engaging with the valve member to close the inlet of the aerating gas. Furthermore, the diaphragm includes a central portion, a peripheral portion attached to the periphery of the base, and a surrounding web segment interposed therebetween. The surrounding web segment includes a plurality of fibrous filaments which are arranged to form a textured structure with a plurality of pores of a dimension such that the aerating gas, when introduced, is permitted to be bubbled through said plurality of pores, so as to form fine and small bubbles in the water.

Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.

Abstract: A device and method for providing illuminating light utilizes quantum dots to convert at least some of the original light emitted from a light source of the device to longer wavelength light to change the color characteristics of the illuminating light. The quantum dots may be included in the light source, a light panel and/or an optional interface medium of the device.

Abstract: A micro-channel heat sink comprises an upper cover layer and a cooling layer. The cooling layer comprises at least one inlet fluid tank, a plurality of micro-channels, and at least one outlet fluid tank. The inlet fluid tank can store and deliver the working fluids, and the outlet fluid tank collects the heated working fluid flowing through the plurality of micro-channels. The plurality of micro-channels are disposed between the inlet fluid tank and the outlet fluid tank, wherein the cross sectional area of each of the micro-channels increases along the direction towards the outlet fluid tank.

Abstract: The present disclosure provides antibody-drug conjugates that are potent cytotoxins, wherein the drug is linked to the antibody through a linker. The disclosure is also directed to compositions containing the antibody-drug conjugates, and to methods of treatment using them.

Abstract: A lighting unit having a light generating section and a base section is disclosed. The base and light generating sections are reversibly connected by a series of mating connectors. The light generating section includes a plurality of groups of LEDs and a mixing structure. The base section includes an adapter that connects the lighting unit to an AC power receptacle designed to receive an incandescent lamp or a fluorescent lamp. The base section also includes a controller that powers the LEDs. The lighting unit also includes a sensor that periodically measures a parameter related to the intensity of light generated by each group of LEDs during the normal operation of the lighting unit. The controller uses this sensor to control the LEDs. The lighting section can also include a housing that has the shape of a conventional incandescent or fluorescent light fixture or light bulb.

Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing a prodrug are also disclosed.

Abstract: A light emitting device in which a primary light generator, such as a light emitting diode (LED) or laser diode, is operable to emit a primary light that is received by a body of wavelength converting material. A portion of the primary light is absorbed by the body of wavelength converting material and is emitted as secondary light. The wavelength converting material contains phosphor nano-particles and larger phosphor particles. The phosphor nano-particles prevent transmission of primary light while the larger phosphor particles provide efficient light conversion.

Abstract: The invention provides a method and system for dynamically estimating background noise. The system includes a portable communication device, a vocoder, and a voice activated detector. Based on information received by the portable communication device, the vocoder determines parameters related to incoming information including a voicing mode indicative of the periodicity of incoming information. The voice activated detector then compares the voicing mode to a threshold to determine whether a background noise estimate should be updated.

Abstract: A communication system (100) for bridging talk groups includes private network communication devices (102) operating within a private network system, and public network communication devices (110, 122, 112) operating within a public network system. At least one communication subsystem (104) is operable with both the private and public network systems. The communication subsystem (104) relays information between the private network communication devices (102) and the public network communication devices (110, 122, 112).

Abstract: A keyboard includes a housing having a number of cavities to slidably receive shanks of a number of key pads, and a light device for lighting the key pads. The lighting device includes a number of light members engaged in the shanks of the key pads, the housing includes two conductive projections extended into each of the cavities to selectively engage with terminals of the light members, and to energize the light members when the key pads are depressed by the users. A spring biasing device may bias the key pad to disengage the terminals of the light members from the conductive projections.

Abstract: A device and method for emitting output light utilizes both quantum dots and non-quantum fluorescent material to convert at least some of the original light emitted from a light source of the device to longer wavelength light to change the color characteristics of the output light. The device can be used to produce broad-spectrum color light, such as white light.

Abstract: A mobile communication device (102) receives information in a broadcast control channel (108) including a page message (108). The mobile communication device measures certain parameters (210) of the control channel, such as received signal strength, channel quality, and the present automatic gain setting. These parameters are scored and weighted (300) to produce a signal quality metric (314) to determine the duration of time the mobile communication device can remain in a low power state to conserve battery charge before checking for page alert message in the broadcast control channel next.

Abstract: A system, method and computer readable medium are provided for segmenting a cache that is shared by multiple processors. According to the method, a first segment of the cache is allocated to a first processor and a second segment of the cache is allocated to a second processor. An execution time of at least one task on the first processor is monitored. If the execution time of the at least one task is greater than an allowed execution time minus a predetermined margin, the size of the first segment of the cache that is allocated to the first processor is increased. In one preferred method, if the execution time of the at least one task is significantly less than the allowed execution time minus the predetermined margin, the size of the first segment of the cache that is allocated to the first processor is decreased.

Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing a prodrug are also disclosed.